Blood
Articles in this Issue
Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy
Abstract Background and Significance Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma (NHL), primarily manifesting a...
Prevalence, clinical correlates and clonal inferences of concurrent splicing factor mutations in patients with myeloid neoplasms
Abstract Introduction: Somatic mutations in splicing factors (SF) - SF3B1, SRSF2, U2AF1, and ZRSR2 – represent one of the most common driver...
Lower dose emicizumab prophylaxis in children with hemophilia A: Real - world outcomes, hemostatic profiles and cost- effectiveness from a resource limited setting
Abstract Background: Although Emicizumab has transformed prophylaxis in Hemophilia A management, standard-dose therapy r...
Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma
Abstract Introduction Nivolumab-AVD has become a new standard for untreated advanced stage Hodgkin lymphoma in North Ame...
Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of cancer associated thrombosis: A systematic review and meta-analysis
Abstract Introduction: Cancer associated thrombosis is a major cause of morbidity and mortality with high risk of recurr...
Impact of GLP-1 agonists on cardiovascular outcomes in patients with sickle cell anemia: A propensity score matched retrospective cohort study
Abstract Background: Sickle Cell Disease (SCD) is associated with worse cardiovascular (CV) outcomes. The Glucagon-like peptide-1 receptor a...
Real-world effectiveness and safety of fostamatinib in difficult-to-treat patients: Results of a three-year registry in France.
Abstract Background: Fostamatinib, a spleen tyrosine kinase inhibitor, has been marketed in France for the management of adult chronic immun...
Transfusion without fear: Real-world outcomes in warm autoimmune hemolytic anemia challenge historical hesitations
Abstract Introduction Warm autoimmune hemolytic anemia (WAIHA) is an acquired autoimmune disorder characterized by IgG-m...
National trends and disparities in mortality involving ischemic heart disease andanemia in the United States, 1999-2023
Abstract Background: Ischemic heart disease (IHD) is a well-established leading cause of death in the United States, contributing significan...
Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis
Abstract Background: Janus Kinase (JAK) inhibitors are the current standard of care for patients (pts) with myelofibrosis (MF). However, man...
Characterization of platelet autoantibody prevalence, serology, and predictive value for progression to immune thrombocytopenia in patients with persistent isolated mild thrombocytopenia (PIMT)
Abstract BACKGROUND Persistent isolated mild thrombocytopenia (PIMT) is a recently defined and soon-to-be formalized immune thrombocytopenia...
Innovating rare disease care: A digital health network for the remote management of acquired Hemophilia A
Abstract Introduction Acquired Hemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder caused by autoantibodies that...
Plasmacytoid dendritic cell-associated acute myeloid leukemia (pDC-AML) a comprehensive review
Abstract Background: Plasmacytoid dendritic cell-associated acute myeloid leukemia (pDC-AML) is an emerging, rare subtype of AML characteriz...
Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma
Abstract Background: B-Cell Maturation Antigen (BCMA)-directed CAR-T therapy has transformed the treatment paradigm for patients with relaps...
Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study
Abstract Introduction Venetoclax combined with hypomethylating agents (VEN/HMA) is an approved frontline induction therapy for older or unfit...
Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia
Abstract Introduction Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, demonstrated promising safety and efficacy in primary imm...
Mitochondrial mass in pre-lymphodepletion T cells predicts early response to CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma
Abstract Background: Response heterogeneity to CAR-T therapy in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) remains a major clinical...
Tyrosine phosphorylation and allosteric regulation of IMPDH2 reveals a novel therapeutic vulnerability in hematologic malignancies
Abstract Background: Inosine monophosphate dehydrogenase 2 (IMPDH2) is a critical rate-limiting enzyme in the de novo guanine nucleotide bio...
Post-allogenic hematopoietic stem cell transplant ( Allo-HSCT), hypomethylating-agent maintenance improves survival without increasing GVHD (Graft versus host disease) in AML/MDS( Acute myeloid leukemia/Myelodysplastic syndrome): Updated systematic review and meta-analysis
Abstract Background Relapse remains the leading cause of treatment failure after allogeneic hematopoietic stem-cell transplantation (allo-HS...
Improvement of sickle cell disease care mitigates the healthcare utilization induced by increased prevalence: Experience of a tertiary pediatric center
Abstract Introduction:Sickle cell disease (SCD) is one of the most frequent monogenic diseases worldwide. SCD has undergone two major change...
Pediatric AML blasts drive immunosuppressive reprogramming and metabolic adaptation in macrophages, impairing T cell activation and anti-leukemic immunity
Abstract Despite transformative impact of immunotherapy in cancer care, patients with acute myeloid leukemia (AML) continue to experience li...
Targeted disruption of BCL11A ZnF4 enhances fetal hemoglobin in β-thalassemia and sickle cell disease: A druggable approach
Abstract Background: β-thalassemia and sickle cell disease (SCD) are severe monogenic disorders resulting from mutations...
Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study
Abstract Background A broad spectrum of methods is used for the evaluation of disease activity and minimal residual dise...
Social determinants outweigh geographic barriers in Acute Myeloid Leukemia survival: Insights from a brazilian multicenter study
Abstract Introduction: Studies from European and North American cohorts have shown that the distance from patient's home from the treatment...
Patients with high-risk features in Mantle Cell Lymphoma: A systematic literature review of clinical trials and real-world studies
Abstract Introduction Given the low incidence of high-risk mantle cell lymphoma (MCL), conducting a systematic review and pooling data acros...